This inventor holds 2 USPTO granted patents and 7 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2024-2025.
Company Filing History:
Years Active: 2024-2025
Title: Eric Jorgenson: Innovator in Skin Cancer Treatment
Introduction
Eric Jorgenson is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of oncology, particularly in the treatment of skin cancer. With a total of 2 patents, Jorgenson's work focuses on innovative methods that aim to improve patient outcomes.
Latest Patents
Jorgenson's latest patents include groundbreaking methods for treating skin cancer. The first patent details methods of treating subjects with skin cancer using histidine ammonia-lyase (HAL) agonists. This patent provides methods for identifying subjects at risk of developing skin cancer, thereby enabling early intervention. The second patent outlines methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors. This innovation also includes methods for identifying individuals at increased risk of developing skin cancer.
Career Highlights
Eric Jorgenson is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in cancer treatment. His work is characterized by a commitment to developing effective therapies that can significantly impact patient care.
Collaborations
Some of Jorgenson's notable coworkers include Aris I Baras and Goncalo Abecasis. Their collaborative efforts contribute to the innovative research environment at Regeneron Pharmaceuticals.
Conclusion
Eric Jorgenson's contributions to the field of skin cancer treatment through his patents and work at Regeneron Pharmaceuticals highlight his dedication to improving healthcare outcomes. His innovative approaches are paving the way for new treatment options for patients at risk of skin cancer.